HETEROGENEOUS TARGETABLE FLT3/NPM1/IDH1 · Heterogeneous Targetable FLT3-ITD / NPM1 / IDH1/2 / DNMT3A γ₁ = 14.134725141734693 · AML · FLT3 · IDH1/2 · NPM1 · venetoclax · tran CANCER BOARD NEURO
AML · ACUTE MYELOID
Driver
FLT3-ITD / NPM1 / IDH1/2 / DNMT3A
Coverage
~4.3/100k · CR rate ~70-80% with targeted therapy
Confidence
STRONG
Open Sorries
⚠ FLT3-ITD resistance after midostaurin
⚠ Secondary AML poor prognosis
⚠ TP53-mutated refractory
HYPOTHESIS
FLT3 inhibitors (midostaurin/gilteritinib) + venetoclax/aza backbone. IDH-mut → ivosidenib/enasidenib.
⚠ OPEN: TP53-mutated AML — no durable CR pathway yet
3Sorries
γ₁14.134725141734693
CATAN CANCER · BLOOD-LEUKEMIA